[company_age]8.0[/company_age][employees]2-10 employees[/employees][funding]Seed[/funding][description]VitroScan is a Dutch biotech company founded in 2016 and based at the Leiden Bio Science Park. The company develops certified predictive ex vivo 3D tumor testing services for reliable treatment response prediction for the clinic and to improve patient stratification for clinical trials. VitroScan's proprietary technology provides highly reproducible drug testing in the native tumor microenvironment (TME). The company's clinical trial program is performed in collaboration with expert clinicians from leading oncology centers. In these trials, patient-specific ex vivo tumor sensitivity to chemo-, targeted, or immunotherapy is correlated to clinical outcomes. VitroScan is dedicated to delivering predictive diagnostic testing to support better informed treatment decisions for cancer patients.[/description][ps]Predictive testing solutions for cancer patients.[/ps]